Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
REGULATORY
No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
As Japan weighs evaluation indicators to gauge generic manufacturers’ efforts on stable supplies, a key reimbursement policy panel on October 27 discussed a specific picture of such criteria and how to use them in drug pricing. No objections were raised…
To read the full story
Related Article
- 120 APIs/Specs to Get Higher-than-Peer Prices with Generic Company Indicators: MHLW Simulation
December 14, 2023
- Japan to Adopt Generic Company Indices for Drug Pricing on Pilot Basis from FY2024
November 20, 2023
- MHLW Panel Proposes Assessing Generic Makers’ Efforts toward Stable Supplies, Reflecting Results in Pricing
October 12, 2023
REGULATORY
- Panelists See Legal Issue over Providers’ Refusal of People Vaccinated with Replicon Shot
September 20, 2024
- MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- MHLW Working Group Gets into Details of Proposed Drug Supply Info System
September 18, 2024
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…